|
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Thrombophilic profile (factor V G1691A (Leiden), factor V H1299R (R2), prothrombin G20210A, MTHFR C677T, MTHFR A1298C, factor XIII V34L, β-fibrinogen-455 G-A and plasminogen activator inhibitor (PAI)-1 4G/5G) was evaluated using the cardiovascular diseases (CVD) StripAssay based on DNA isolation, PCR and reverse hybridisation.
|
31300468 |
2019 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Neutrophil to lymphocyte ratio, ceruloplasmin, alpha1-antitrypsin and soluble urokinase plasminogen activator receptor predicted increased risk of CVD but not DM, while haptoglobin and complement C3 showed the opposite pattern.
|
29895294 |
2018 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Soluble Urokinase Plasminogen Activator Receptor is Associated with Coronary Artery Calcification and Cardiovascular Disease in Patients Undergoing Hemodialysis.
|
29734173 |
2018 |
|
Cardiovascular Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Thrombotic factors such as increased levels of plasminogen activator inhibitor, fibrinogen, lipoprotein (a) and homocysteine have been shown to be associated with increased CVD.
|
28505046 |
2017 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Cadmium exposure is associated with soluble urokinase plasminogen activator receptor, a circulating marker of inflammation and future cardiovascular disease.
|
27792942 |
2017 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Because PLG and Lp(a) associate with human CVD risk, interplay among the proteins might affect atherosclerosis by regulating cholesterol efflux from macrophages.
|
28768900 |
2017 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Plasma plasminogen activator inhibitor (PAI)-1, a potent inhibitor of plasminogen activation and fibrinolysis, is increased in many clinical situations associated with high incidence of CVD.
|
26884864 |
2015 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Epidemiological studies suggest whole grain consumption is associated with a reduced risk of cardiovascular disease (CVD), possibly through alterations in glucose metabolism and subsequent effects on plasminogen activator inhibitor (PAI)-1, a novel biomarker for CVD.
|
21195592 |
2012 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Plasminogen activator inhibitor type-1 (PAI-1) has already been associated with atherosclerosis; myocardial infarction; and cardiovascular disease risk factors such as obesity, insulin resistance, and dyslipidemia.
|
20127289 |
2010 |
|
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The less efficient proteolytic processing of the Pro370Leu protein by plasmin, coupled with the strong association of this variant with ethnicity, suggests that the Pro370Leu CHGA gene variant may contribute to the differential prevalence of cardiovascular disease across ethnic groups.
|
17991725 |
2008 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
This study tested whether feelings of personal control over one's life circumstances (i.e., personal mastery) would attenuate the relations between stress (i.e., negative life events and caregiving distress) and Plasminogen Activator Inhibitor (PAI)-1 antigen, an inhibitor of fibrinolysis implicated in the development of cardiovascular disease.
|
18377159 |
2008 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Overexpression of plasminogen activator inhibitor-1 (SERPINE1, PAI-1), the major physiological inhibitor of pericellular plasmin generation, is a significant causative factor in the progression of vascular disorders (e.g. arteriosclerosis, thrombosis, perivascular fibrosis) as well as a biomarker and a predictor of cardiovascular-disease associated mortality.
|
19132220 |
2008 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Plasma plasminogen activator inhibitor (PAI)-1, a potent inhibitor of fibrinolysis, is elevated in a number of clinical situations that are associated with high incidence of CVD.
|
17485272 |
2007 |
|
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The 4G allele in the promoter region of the plasminogen activator inhibitor type 1 (PAI-1) gene is associated with higher plasma PAI-1 levels and activity, but its association with cardiovascular diseases is unclear.
|
17161063 |
2006 |
|
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
High levels of plasminogen activator inhibitor type 1 (PAI-1) have been implicated as a risk factor for cardiovascular disease, but its precise role remains controversial.
|
15630497 |
2005 |
|
Cardiovascular Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Plasminogen activator inhibitor type 1 (PAI-1) is the main inhibitor of fibrinolysis, and high levels may increase the risk of cardiovascular disease.
|
14605330 |
2003 |
|
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
An association between an increase in plasminogen activator inhibitor type 1 (PAI-1) and obesity, and also between elevated levels of PAI-1 and the presence of PAI-1 promoter 4G allele has been described in adults and can contribute to increased risk of cardiovascular disease.
|
11522017 |
2001 |
|
Cardiovascular Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Increased expression of plasminogen activator inhibitor type 1 (PAI-1) is now considered as an independent risk factor for cardiovascular disease.
|
11567663 |
2001 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Many prospective studies have reported an unadjusted positive association between plasma fibrinolytic markers (eg, tissue plasminogen activator antigen or plasminogen activator inhibitor antigen) and risk of cardiovascular disease.
|
11209988 |
2000 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Using these techniques, three major proteolytic systems -- the plasminogen, the matrix metalloproteinase (MMP) and the coagulation systems -- have been shown to be involved in cardiovascular diseases, which still constitute the leading cause of death in Western societies.
|
11122772 |
2000 |
|
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Plasma levels of type 1 plasminogen activator inhibitor (PAI-1), a risk factor for cardiovascular disease, are elevated in obese subjects, especially those with omental fat accumulation.
|
10566656 |
1999 |